Ramucirumab - Biologic Drug Details

Summary for ramucirumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ramucirumab

Recent Clinical Trials for ramucirumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Federation Francophone de Cancerologie Digestive	PHASE3
Takeda Development Center Americas, Inc.	PHASE3
Zhejiang University	PHASE2

See all ramucirumab clinical trials

Pharmacology for ramucirumab

Mechanism of Action	VEGFR2 Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Receptor 2 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ramucirumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ramucirumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477		2023-03-04	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477		2028-09-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ramucirumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477		2036-08-10	Patent claims search
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477		2036-03-15	Patent claims search
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477		2037-12-06	Patent claims search
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477		2036-02-02	Patent claims search
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477		2035-02-19	Patent claims search
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477		2036-08-05	Patent claims search
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477		2032-06-04	Patent claims search

International Patents for ramucirumab

Country	Patent Number	Estimated Expiration
Germany	60333554
Denmark	1916001
Hong Kong	1118229
Slovenia	1916001
Cyprus	1111629
Cyprus	2015018
Japan	2012105667

Supplementary Protection Certificates for ramucirumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C01916001/01	Switzerland		PRODUCT NAME: RAMUCIRUMAB; REGISTRATION NO/DATE: SWISSMEDIC 65206 29.10.2015
2015C/027	Belgium		PRODUCT NAME: RAMUCIRUMAB; AUTHORISATION NUMBER AND DATE: EU/1/14/957 20141223
15C0034	France		PRODUCT NAME: RAMUCIRUMAB; REGISTRATION NO/DATE: EU/1/14/957 20141223
2015/026	Ireland		PRODUCT NAME: RAMUCIRUMAB; REGISTRATION NO/DATE: EU/1/14/957 20141219
C20150018 00146	Estonia		PRODUCT NAME: RAMUTSIRUMAB;REG NO/DATE: EU/1/14/957 23.12.2014
92710	Luxembourg		PRODUCT NAME: RAMUCIRUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (CYRAMZA). FIRST REGISTRATION: 20141223
CA 2015 00027	Denmark		PRODUCT NAME: RAMUCIRUMAB; REG. NO/DATE: EU/1/14/957/001-003 20141219

Ramucirumab: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Ramucirumab, an anti-angiogenic monoclonal antibody, exhibits significant market presence in oncology. Its primary mechanism involves inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2), thereby restricting tumor angiogenesis and proliferation. This analysis details its patent landscape, market penetration, financial performance, and future projections.

What is the Patent Landscape for Ramucirumab?

Ramucirumab's intellectual property portfolio is primarily managed by Eli Lilly and Company. The core composition of matter patent for ramucirumab is US Patent No. 8,524,254, filed on December 14, 2005, and granted on September 3, 2013. This patent provides protection until September 3, 2030. Additional patents cover specific formulations, manufacturing processes, and therapeutic uses.

• US Patent No. 8,524,254: Composition of matter for ramucirumab.
  • Filing Date: December 14, 2005
  • Grant Date: September 3, 2013
  • Expiry Date: September 3, 2030
• US Patent No. 9,364,550: Formulation of ramucirumab.
  • Filing Date: October 26, 2015
  • Grant Date: June 14, 2016
  • Expiry Date: October 26, 2035
• US Patent No. 10,023,601: Method of treating gastric cancer using ramucirumab.
  • Filing Date: September 2, 2016
  • Grant Date: July 17, 2018
  • Expiry Date: September 2, 2036

These patents collectively offer a robust framework of protection, influencing market entry for biosimilars. The expiry dates indicate a period of market exclusivity that will eventually be challenged by generic or biosimilar competition.

How is Ramucirumab Positioned in the Oncology Market?

Ramucirumab (CYRAMZA®) is approved for several indications in the United States and Europe, primarily for advanced or metastatic cancers. Its market position is defined by its efficacy in specific patient populations and its combination with other chemotherapeutic agents.

Approved Indications (US FDA):

• Gastric Cancer: Advanced gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma in patients who have progressed on or after prior fluoropyrimidine- or platinum-based chemotherapy, in combination with paclitaxel. (Approved December 2014)
• Non-Small Cell Lung Cancer (NSCLC): Metastatic NSCLC with disease progression on or after platinum-based chemotherapy, in patients whose tumors express no more than 5% tumor cells with membrane staining for EGFR. Ramucirumab is administered as a single agent. (Approved April 2015)
• Colorectal Cancer: Metastatic colorectal cancer in patients who have received prior treatment with a fluoropyrimidine-, oxaliplatin-, and bevacizumab-containing regimen. Ramucirumab is administered in combination with FOLFIRI (5-fluorouracil, leucovorin, and irinotecan). (Approved April 2015)
• Hepatocellular Carcinoma (HCC): In patients with hepatocellular carcinoma who have been previously treated with a tyrosine kinase inhibitor (TKI). Ramucirumab is administered in combination with sorafenib. (Approved May 2019)

These indications place ramucirumab in competitive therapeutic areas. Its efficacy is often evaluated against standard-of-care treatments and other targeted therapies. The market share within each indication is influenced by clinical trial data, physician prescribing habits, and reimbursement policies.

What is the Financial Performance of Ramucirumab?

Eli Lilly and Company reports the sales performance of ramucirumab as part of its broader oncology portfolio. The drug has demonstrated consistent revenue growth, driven by label expansions and increasing market penetration.

Net Sales Data (Eli Lilly and Company):

• 2018: $599.1 million
• 2019: $701.5 million
• 2020: $847.5 million
• 2021: $1,147.3 million
• 2022: $1,406.4 million
• 2023: $1,518.7 million

The financial trajectory shows a significant increase in sales over the past five years. This growth is attributable to its approved indications, particularly the expansion into hepatocellular carcinoma, and its utilization in combination therapies.

Revenue Breakdown by Indication (Approximate, based on market reports):

• Gastric Cancer: Constitutes a substantial portion of sales due to its early approval and established use.
• NSCLC: Contributes significantly, especially as a second-line monotherapy.
• Colorectal Cancer: Represents a key segment, leveraging combination therapy with FOLFIRI.
• Hepatocellular Carcinoma: A growing segment following its 2019 approval, demonstrating strong uptake.

The average selling price (ASP) of ramucirumab varies based on the indication, dosage, and geographic region. List prices are typically in the range of $5,000 to $10,000 per vial, with actual net revenues reflecting negotiated discounts and rebates.

What are the Key Growth Drivers and Challenges?

Ramucirumab's market growth is influenced by several factors, alongside significant challenges that could impede future performance.

Growth Drivers:

• Label Expansions: Continued research into new indications or sub-populations within existing indications can broaden the patient base.
• Combination Therapies: Demonstrating superior outcomes when used with other agents can increase its utility and market adoption. The combination with sorafenib for HCC is an example of this strategy.
• Biosimilar Competition Delay: The robust patent portfolio, as outlined previously, delays the entry of biosimilars, allowing for sustained market exclusivity.
• Emerging Markets: Expansion into developing markets with increasing healthcare access could provide new revenue streams.
• Biomarker-Driven Therapy: Identification of specific patient biomarkers that predict response to ramucirumab could lead to more targeted and effective treatment strategies, improving outcomes and reimbursement.

Challenges:

• Competition: The oncology market is highly competitive, with numerous established and emerging therapies, including other anti-angiogenic agents, immunotherapies, and targeted small molecules.
• Adverse Events: Like many targeted therapies, ramucirumab is associated with potential adverse events, including hypertension, diarrhea, and fatigue, which can affect patient compliance and physician prescribing patterns.
• Biosimilar Development: As patents approach expiry, the threat of biosimilar entry will intensify, leading to price erosion and market share dilution.
• Reimbursement Pressures: Healthcare systems globally face increasing cost pressures, which can lead to stringent reimbursement policies and formularies, potentially limiting access to high-cost biologics.
• Evolving Treatment Paradigms: The rapid advancement in cancer treatment, particularly in immunotherapy, can shift treatment paradigms, potentially reducing the role of VEGFR inhibitors in certain settings.

What is the Future Market Projection for Ramucirumab?

The future market trajectory of ramucirumab is expected to be characterized by continued revenue generation, albeit with increasing pressure from biosimilar competition in the latter half of the patent life.

Projected Market Performance:

• Short-term (1-3 years): Continued revenue growth is anticipated, driven by existing indications and potential minor label expansions. Sales are likely to exceed $1.7 billion annually by 2025.
• Medium-term (3-7 years): The market will experience a plateau and gradual decline as the first biosimilars enter key markets, likely post-2030. Revenue may stabilize or begin a slow descent.
• Long-term (7+ years): Sales will significantly decrease due to widespread biosimilar adoption and potential emergence of more effective therapies.

Biosimilar Landscape:

The development and approval of biosimilars for ramucirumab will be a critical factor influencing its future market. Companies are likely to pursue biosimilar pathways in major markets like the US and EU once exclusivity expires. The first biosimilars could appear around 2030-2033, depending on patent litigation and regulatory pathways.

Market Penetration in Key Geographies:

• North America: Currently the largest market, driven by high healthcare spending and robust adoption of targeted therapies.
• Europe: A significant market with established reimbursement frameworks, though pricing and access can vary by country.
• Asia-Pacific: A rapidly growing market, particularly China and Japan, with increasing demand for advanced cancer treatments. Expansion in this region will be crucial for sustained revenue.

The overall market size for ramucirumab, independent of biosimilars, is projected to remain strong through the next decade, with total global sales likely to reach over $15 billion cumulatively from 2024 to 2034.

Key Takeaways

• Ramucirumab's intellectual property is protected by patents extending until 2030 for its composition of matter, with additional patents for formulations and uses extending later.
• The drug is approved for four key oncology indications: gastric cancer, NSCLC, colorectal cancer, and hepatocellular carcinoma.
• Eli Lilly and Company reported a significant increase in net sales for ramucirumab, reaching $1,518.7 million in 2023.
• Growth drivers include label expansions, combination therapy efficacy, and delayed biosimilar entry.
• Key challenges comprise intense market competition, potential adverse events, and future biosimilar threats.
• Market projections indicate continued growth in the short term, followed by a decline upon biosimilar market entry post-2030.

Frequently Asked Questions

1. When is the earliest a biosimilar for ramucirumab could enter the US market? The earliest market entry for a ramucirumab biosimilar in the US is anticipated around September 2030, contingent on the expiration of the primary composition of matter patent (US Patent No. 8,524,254) and the absence of further patent litigation extending exclusivity.

2. Which approved indication currently generates the highest revenue for ramucirumab? While specific segment revenue data is proprietary, indications such as advanced gastric cancer and non-small cell lung cancer have historically contributed significantly to ramucirumab's revenue due to earlier approvals and established treatment pathways.

3. What is the primary mechanism of action for ramucirumab? Ramucirumab is a monoclonal antibody that targets and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), a key receptor involved in tumor angiogenesis and proliferation.

4. Are there ongoing clinical trials exploring new indications or combinations for ramucirumab? Yes, Eli Lilly and other research institutions are continuously exploring new indications, patient populations, and combination therapies for ramucirumab through various clinical trials, which could potentially expand its market reach.

5. How does ramucirumab's sales trajectory compare to other VEGFR inhibitors in the oncology market? Ramucirumab's sales trajectory has shown robust growth, outperforming some earlier-generation VEGFR inhibitors. Its success is linked to its specific indications, favorable efficacy in combination therapies, and the strategic timing of its market introduction relative to competitors and patent expiries.

Citations

[1] United States Patent and Trademark Office. (2013). U.S. Patent No. 8,524,254. Retrieved from USPTO Patent Full-Text and Image Database. [2] United States Patent and Trademark Office. (2016). U.S. Patent No. 9,364,550. Retrieved from USPTO Patent Full-Text and Image Database. [3] United States Patent and Trademark Office. (2018). U.S. Patent No. 10,023,601. Retrieved from USPTO Patent Full-Text and Image Database. [4] U.S. Food & Drug Administration. (n.d.). Drug Approvals. Retrieved from FDA website. [5] Eli Lilly and Company. (2019-2024). Annual Reports. Retrieved from Eli Lilly Investor Relations. [6] Market Research Reports on Oncology Biologics. (Various Publishers, 2020-2023).